Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2026-05-22 @ 12:57 PM
Study NCT ID:
NCT05278351
Status:
UNKNOWN
Last Update Posted:
2023-03-31
First Post:
2022-03-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Tislelizumab Plus Cetuximab and Irinotecan vs Third-line Standard-of-care in Refractory mCRC
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Colorectal Neoplasms Malignant | View |
Keywords: